United Super Pty LTD In Its Capacity As Trustee For The Construction & Building Unions Superannuation Fund Bristol Myers Squibb CO Transaction History
United Super Pty LTD In Its Capacity As Trustee For The Construction & Building Unions Superannuation Fund
- $2.45 Billion
- Q2 2025
A detailed history of United Super Pty LTD In Its Capacity As Trustee For The Construction & Building Unions Superannuation Fund transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, United Super Pty LTD In Its Capacity As Trustee For The Construction & Building Unions Superannuation Fund holds 17,700 shares of BMY stock, worth $807,474. This represents 0.03% of its overall portfolio holdings.
Number of Shares
17,700
              Previous 17,700
              
        
           -0.0%
        
      
          
        Holding current value
$807,474
            Previous $1.08 Million
            
        
           24.1%
        
      
          
        % of portfolio
0.03%
            Previous 0.05%
          
        Shares
	  2 transactions
	
  Others Institutions Holding BMY
# of Institutions
2,664Shares Held
1.64BCall Options Held
22.4MPut Options Held
25.3M- 
    
      Vanguard Group Inc Valley Forge, PA195MShares$8.89 Billion0.15% of portfolio
- 
    
      Black Rock Inc. New York, NY159MShares$7.24 Billion0.15% of portfolio
- 
    
      Jpmorgan Chase & CO New York, NY108MShares$4.93 Billion0.52% of portfolio
- 
    
      State Street Corp Boston, MA94.7MShares$4.32 Billion0.17% of portfolio
- 
    
      Charles Schwab Investment Management Inc San Francisco, CA70.8MShares$3.23 Billion0.59% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $97B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...